BioCardia Says FDA Completes Review Of Proposed Adaptive Statistical Analysis Design For Ongoing CardiAMP Cell Therapy In Heart Failure Pivotal Study
Portfolio Pulse from Benzinga Newsdesk
BioCardia announced that the FDA has completed its review of the proposed adaptive statistical analysis design for the ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study. The plan is set to be implemented at the DSMB meeting on July 12, 2023.
June 20, 2023 | 9:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioCardia's stock may be positively impacted by the FDA's completion of the review for the CardiAMP Cell Therapy in Heart Failure Pivotal Study's adaptive statistical analysis design.
The FDA's completion of the review for the adaptive statistical analysis design is a positive development for BioCardia, as it indicates progress in the ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study. This news may be seen as a positive signal by investors, potentially leading to an increase in the stock price of BCDA in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100